BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design. 1997

P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244, USA.

A series of 94 benzoic acid derivatives was synthesized and tested for its ability to inhibit influenza neuraminidase. The enzyme-inhibitor complex structure was determined by X-ray crystallographic analysis for compounds which inhibited the enzyme. The most potent compound tested in vitro, 5 (4-acetylamino)-3-guanidinobenzoic acid), had an IC50 = 2.5 x 10(-6) M against N9 neuraminidase. Compound 5 was oriented in the active site of the neuraminidase in a manner that was not predicted from the reported active site binding of GANA (4) with neuraminidase. In a mouse model of influenza, 5 did not protect the mice from weight loss due to the influenza virus when dosed intranasally.

UI MeSH Term Description Entries
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D009439 Neuraminidase An enzyme that catalyzes the hydrolysis of alpha-2,3, alpha-2,6-, and alpha-2,8-glycosidic linkages (at a decreasing rate, respectively) of terminal sialic residues in oligosaccharides, glycoproteins, glycolipids, colominic acid, and synthetic substrate. (From Enzyme Nomenclature, 1992) Sialidase,Exo-alpha-Sialidase,N-Acylneuraminate Glycohydrolases,Oligosaccharide Sialidase,Exo alpha Sialidase,Glycohydrolases, N-Acylneuraminate,N Acylneuraminate Glycohydrolases,Sialidase, Oligosaccharide
D009975 Orthomyxoviridae A family of RNA viruses causing INFLUENZA and other respiratory diseases. Orthomyxoviridae includes INFLUENZAVIRUS A; INFLUENZAVIRUS B; INFLUENZAVIRUS C; INFLUENZAVIRUS D; ISAVIRUS; and THOGOTOVIRUS. Influenza Viruses,Myxoviruses,Orthomyxoviruses,Influenza Virus,Myxovirus,Orthomyxovirus
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D001565 Benzoates Derivatives of BENZOIC ACID. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the carboxybenzene structure. Benzoate,Benzoic Acids,Acids, Benzoic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Benzoic acid inhibitors of influenza virus neuraminidase.
July 1995, Acta crystallographica. Section D, Biological crystallography,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Design, synthesis, and bioassay of 4-thiazolinone derivatives as influenza neuraminidase inhibitors.
March 2021, European journal of medicinal chemistry,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Design, synthesis and biological evaluation of honokiol derivatives as influenza neuraminidase inhibitors.
November 2019, Journal of Asian natural products research,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Structure-based design of 5'-substituted 1,2,3-triazolylated oseltamivir derivatives as potent influenza neuraminidase inhibitors.
March 2021, RSC advances,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Design, synthesis and biological activity of thiazolidine-4-carboxylic acid derivatives as novel influenza neuraminidase inhibitors.
April 2011, Bioorganic & medicinal chemistry,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Design and one-pot synthesis of 2-thiazolylhydrazone derivatives as influenza neuraminidase inhibitors.
August 2017, Molecular diversity,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors.
August 2011, Journal of enzyme inhibition and medicinal chemistry,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Bioassay of ferulic acid derivatives as influenza neuraminidase inhibitors.
January 2020, Archiv der Pharmazie,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Synthesis and evaluation of 1,4,5,6-tetrahydropyridazine derivatives as influenza neuraminidase inhibitors.
July 1999, Bioorganic & medicinal chemistry letters,
P Chand, and Y S Babu, and S Bantia, and N Chu, and L B Cole, and P L Kotian, and W G Laver, and J A Montgomery, and V P Pathak, and S L Petty, and D P Shrout, and D A Walsh, and G M Walsh
Acyl amino acid derivatives as novel inhibitors of influenza neuraminidase.
May 1997, Bioscience, biotechnology, and biochemistry,
Copied contents to your clipboard!